1. GPCR/G Protein
  2. mGluR

Mavoglurant (Synonyms: AFQ056)

Cat. No.: HY-15257 Purity: 99.74% ee.: 99.90%
Data Sheet SDS Handling Instructions

Mavoglurant is a structurally novel, non-competitive mGlu5 receptor antagonist, has an IC50 of 30 nM in a functional assay with human mGluR5.

For research use only. We do not sell to patients.
Mavoglurant Chemical Structure

Mavoglurant Chemical Structure

CAS No. : 543906-09-8

Size Price Stock Quantity
10 mM * 1 mL in DMSO $385 In-stock
5 mg $350 In-stock
10 mg $450 In-stock
50 mg $1500 In-stock
100 mg $2100 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Other Forms of Mavoglurant:

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References

Description

Mavoglurant is a structurally novel, non-competitive mGlu5 receptor antagonist, has an IC50 of 30 nM in a functional assay with human mGluR5. IC50 value: 30 nM Target: mGluR5 in vitro: Mavoglurant is a selective non-competitive antagonist which showed efficacy in the treatment of L-dopa induced dyskinesias in Parkinson's disease and Fragile X mental retardation in proof of principle studies. Mavoglurant is selective over the other mGluR subtypes, iGluRs and a panel of 238 CNS relevant receptors, transporter or enzymes. [1] In vivo: Mavoglurant shows an improved pharmacokinetic profile in rat and efficacy in the stress-induced hyperthermia test in mice as compared to the prototypic mGluR5 antagonist MPEP.[1]

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT01456663 Novartis Pharmaceuticals|Novartis Hepatic Impairment May 2011 Phase 1
NCT01491932 Novartis Pharmaceuticals|Novartis Dyskinesias|Parkinson Disease|Movement Disorders|Parkinsonian Disorders|Anti-Dyskinesia Agents March 2012 Phase 2
NCT01433354 Novartis Pharmaceuticals|Novartis Fragile X Syndrome November 2011 Phase 2|Phase 3
NCT01348087 Novartis Pharmaceuticals|Novartis Fragile X Syndrome August 2011 Phase 2
NCT01019473 Novartis Pharmaceuticals|Novartis Huntington's Disease|Chorea November 2009 Phase 2
NCT01813019 Novartis Pharmaceuticals|Novartis Patient Diagnosed With OCD and Resistant to SSRI Treatment|Failed SSRI Over 12 Weeks at Appropriate Doses November 2013 Phase 2
NCT01491529 Novartis Pharmaceuticals|Novartis Dyskinesias|Parkinson Disease|Movement Disorders|Parkinsonian Disorders|Anti-Dyskinesia Agents April 2012 Phase 2
NCT01385592 Novartis Pharmaceuticals|Novartis Dyskinesias|Parkinson Disease|Movement Disorders|Parkinsonian Disorders November 2011 Phase 2
NCT02920892 Elizabeth Berry-Kravis|National Institute of Neurological Disorders and Stroke (NINDS)|Rush University Medical Center Fragile X Syndrome June 5, 2017 Phase 2
NCT00888004 Novartis Parkinson's Disease|L-dopa Induced Dyskinesia March 2009 Phase 2
NCT01173731 Novartis Pharmaceuticals|Novartis Parkinson Disease|Dyskinesia, Drug-Induced|Levodopa October 2010 Phase 2
NCT00582673 Novartis Parkinson's Disease October 2007 Phase 2
NCT01357239 Novartis Pharmaceuticals|Novartis Fragile X Syndrome May 2011 Phase 2
NCT01253629 Novartis Pharmaceuticals|Novartis Fragile X Syndrome November 2010 Phase 2
NCT00414856 Novartis Gastroesophageal Reflux Disease August 2006 Phase 1
NCT01482143 Novartis Pharmaceuticals|Novartis Fragile X Syndrome March 2012 Phase 1
NCT01442259 Novartis Pharmaceuticals|Novartis Mild Moderate|or Severe Renal Impairment January 2011 Phase 1
NCT01092065 Novartis Parkinson's Disease March 2010 Phase 2
NCT00986414 Novartis Parkinson Disease|Dyskinesias September 2009 Phase 2
NCT01456663 Novartis Pharmaceuticals|Novartis Hepatic Impairment May 2011 Phase 1
NCT01491932 Novartis Pharmaceuticals|Novartis Dyskinesias|Parkinson Disease|Movement Disorders|Parkinsonian Disorders|Anti-Dyskinesia Agents March 2012 Phase 2
NCT01433354 Novartis Pharmaceuticals|Novartis Fragile X Syndrome November 2011 Phase 2|Phase 3
NCT01348087 Novartis Pharmaceuticals|Novartis Fragile X Syndrome August 2011 Phase 2
NCT01019473 Novartis Pharmaceuticals|Novartis Huntington's Disease|Chorea November 2009 Phase 2
NCT01813019 Novartis Pharmaceuticals|Novartis Patient Diagnosed With OCD and Resistant to SSRI Treatment|Failed SSRI Over 12 Weeks at Appropriate Doses November 2013 Phase 2
NCT01491529 Novartis Pharmaceuticals|Novartis Dyskinesias|Parkinson Disease|Movement Disorders|Parkinsonian Disorders|Anti-Dyskinesia Agents April 2012 Phase 2
NCT01385592 Novartis Pharmaceuticals|Novartis Dyskinesias|Parkinson Disease|Movement Disorders|Parkinsonian Disorders November 2011 Phase 2
NCT02920892 Elizabeth Berry-Kravis|National Institute of Neurological Disorders and Stroke (NINDS)|Rush University Medical Center Fragile X Syndrome June 5, 2017 Phase 2
NCT00888004 Novartis Parkinson's Disease|L-dopa Induced Dyskinesia March 2009 Phase 2
NCT01173731 Novartis Pharmaceuticals|Novartis Parkinson Disease|Dyskinesia, Drug-Induced|Levodopa October 2010 Phase 2
NCT00582673 Novartis Parkinson's Disease October 2007 Phase 2
NCT01357239 Novartis Pharmaceuticals|Novartis Fragile X Syndrome May 2011 Phase 2
NCT01253629 Novartis Pharmaceuticals|Novartis Fragile X Syndrome November 2010 Phase 2
NCT00414856 Novartis Gastroesophageal Reflux Disease August 2006 Phase 1
NCT01482143 Novartis Pharmaceuticals|Novartis Fragile X Syndrome March 2012 Phase 1
NCT01442259 Novartis Pharmaceuticals|Novartis Mild Moderate|or Severe Renal Impairment January 2011 Phase 1
NCT01092065 Novartis Parkinson's Disease March 2010 Phase 2
NCT00986414 Novartis Parkinson Disease|Dyskinesias September 2009 Phase 2
View MoreCollapse
References
Preparing Stock Solutions
Concentration Volume (DMSO) Mass 1 mg 5 mg 10 mg
1 mM 3.1909 mL 15.9546 mL 31.9091 mL
5 mM 0.6382 mL 3.1909 mL 6.3818 mL
10 mM 0.3191 mL 1.5955 mL 3.1909 mL
References
Molecular Weight

313.39

Formula

C₁₉H₂₃NO₃

CAS No.

543906-09-8

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

DMSO: ≥ 47 mg/mL

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Mavoglurant
Cat. No.:
HY-15257
Quantity: